Results 21 to 30 of about 209,106 (262)

Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials

Frontiers in Immunology, 2022
Neoadjuvant chemoradiotherapy (NCRT) plus radical esophagectomy is currently the standard treatment for resectable esophageal or gastroesophageal junction (GEJ) carcinoma.
Jie Zhu, Xuefeng Leng, Binyang Gao, Bo Wang, Hanlin Zhang, Lei Wu, Jiabao Ma, Yan Tan, Lin Peng, Yongtao Han, Qifeng Wang   +10 more
doaj   +1 more source

miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer

Molecular Oncology, 2019
One of the hallmarks of cancer is sustained angiogenesis. Favorable results have been reported in some breast cancer (BC) patients receiving antiangiogenic therapy with bevacizumab (Bev) in combination with chemotherapy, and further knowledge on how Bev ...
Evita Maria Lindholm, Miriam Ragle Aure, Mads Haugland Haugen, Kristine Kleivi Sahlberg, Vessela N. Kristensen, Daniel Nebdal, Anne‐Lise Børresen‐Dale, Ole Christian Lingjærde, Olav Engebraaten   +8 more
doaj   +1 more source

Perioperative systemic therapies for non-small-cell lung cancer: Recent advances and future perspectives

Frontiers in Surgery, 2023
The mainstay of treatment for early-stage non-small-cell lung cancer (NSCLC) is surgical resection. Traditionally, chemotherapy has been used perioperatively in locally extensive disease to improve the oncologic outcomes of surgery, with a 5-year ...
Savvas Lampridis, Marco Scarci
doaj   +1 more source

Antitumor efficacy of silver nanoparticles reduced with β-D-glucose as neoadjuvant therapy to prevent tumor relapse in a mouse model of breast cancer

Frontiers in Pharmacology
Introduction: Neoadjuvant therapy constitutes a valuable modality for diminishing tumor volume prior to surgical resection. Nonetheless, its application encounters limitations in the context of recurrent tumors, which manifest resistance to conventional ...
Moisés Armides Franco Molina, David Reding Hernández, Paola Leonor García Coronado, Jorge R. Kawas, Diana G. Zárate Triviño, Sara Paola Hernández Martínez, Beatriz Elena Castro Valenzuela, Cristina Rodríguez Padilla   +7 more
doaj   +1 more source

Neoadjuvant chemotherapy in 13 patients with locally advanced poorly differentiated thyroid carcinoma based on Turin proposal - a single institution experience

Radiology and Oncology, 2015
Background. There is a paradigm that chemotherapy is ineffective in thyroid carcinoma. The aim of our study was to find out whether neoadjuvant chemotherapy before thyroid surgery had an effect on the size of primary tumour in patients with poorly ...
Besic Nikola, Dremelj Marta, Schwartzbartl-Pevec Andreja, Gazic Barbara   +3 more
doaj   +1 more source

Neoadjuvant chemotherapy is associated with a high rate of perioperative blood transfusion at the time of interval cytoreductive surgery

BMC Cancer, 2018
Background The oncologic safety of allogeneic blood transfusion in ovarian cancer patients is unknow. We sought to determine the prevalence and oncologic safety of perioperative allogeneic blood transfusion during interval cytoreduction surgery among ...
Kevin W McCool, Emmanuel Sampene, Brock Polnaszek, Joseph Connor, Erin E Medlin, Lisa Barroilhet   +5 more
doaj   +1 more source

Efficacy and safety of neoadjuvant systemic therapy in resectable hepatocellular carcinoma: a Systematic Review and meta-analysis

Frontiers in Oncology
BackgroundNeoadjuvant systemic therapy has been shown to benefit patients with solid tumors such as breast cancer and colorectal cancer, but its application in hepatocellular carcinoma (HCC) is still in the exploratory stage, with no established ...
Dongdong Wu, Ning Liu, Hao Dong, Kan Zhou, Lei Du, Ying Li, Yanjun Chao, Fuping Ma   +7 more
doaj   +1 more source

Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion

Indian Journal of Urology, 2012
Introduction: Chemotherapy was shown to improve survival in patients undergoing radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). The initiation and completion rates for perioperative chemotherapy are variable.
Ahmed Eldefrawy, Mark S Soloway, Devendar Katkoori, Rakesh Singal, David Pan, Murugesan Manoharan   +5 more
doaj   +1 more source

Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus

, 2013
AIM: To assess tumour regression grade (TRG) and lymph node downstaging to help define patients who benefit from neoadjuvant chemotherapy.METHODS: Two hundred and eighteen consecutive patients with adenocarcinoma of the esophagus or gastro-esophageal ...
Kelly, Jamie, Iveson, T., Underwood, T.J., Rees, Charlotte, Bailey, Ian, Bateman, Andrew R., Byrne, James, Sharland, Donna, Noble, Fergus, Bateman, Adrian C., Nolan, Luke   +10 more
core   +1 more source

Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer

OncoImmunology, 2021
This review details the clinical utility of Immunoscore, measuring the immune response to cancer within the tumor microenvironment, in bladder cancer. Immunoscore was recently introduced into ESMO Clinical Practice Guidelines for gastrointestinal cancer ...
Elise F. Nassif, Constance Thibault, Stéphane Oudard, Jérôme Galon   +3 more
doaj   +1 more source